The importance the tumor microenvironment plays in the development and metastasis of cancer is turning a new page in cancer research, treatment and prevention. As scientists work to unlock cancer’s genetic code, they are developing new understandings into how cancer cells communicate and the switches that turn tumor development on and off. At the core of many new discoveries is the complex relationship between cancer tumor cells and the microenvironment in which they develop.
European cancer researchers were early to recognize the importance of the tumor microenvironment. According to a 2010 Italian study, “Microenvironment components play a pivotal role in the regulation of the angiogenic switch and in cancer progression.” (Angiogenesis is the growth of new blood vessels necessary for tumor growth.) The Italian study concluded:
“The comprehension of biological and molecular mechanisms involved in the relationship between tumor cells and the microenvironment could unveil new therapeutic and preventive approaches to cancer.”
Within two years, European cancer researchers were conducting clinical applications of cancer therapies that targeted the tumor microenvironment, which a 2012 Belgian study called “an essential ingredient of cancer malignancy.” According to researchers at the Laboratory of Tumor and Development Biology at the University of Liège:
“The malignant features of cancer cells cannot be manifested without an important interplay between cancer cells and their local environment. … Thus in the clinical setting the targeting of the tumor microenvironment to encapsulate or destroy cancer cells in their local environment has become mandatory.”
One thing that distinguishes Issels Integrated Oncology from other U.S. cancer treatment programs is our use of integrative immunotherapy to specifically target the cancer tumor microenvironment.
Organic products and sustainable living reflect a modern recognition of the value of keeping life close to nature. A century or so ago nearly everyone lived a sustainable lifestyle and ate locally-sourced, home-grown food; there weren’t any other options. But since the Industrial Revolution man has been moving farther and farther away from his natural roots. In the process we have exposed our bodies to some very unnatural things: chemicals, plastics, petroleum distillates, nitrates, heavy metals, etc.
Toxic substances have become part of our everyday lives. They are in the foods we eat, the clothes we wear, the construction materials used to build the homes we live in, the toys our children play with. Few of the items used to live a modern life seem to be completely free of toxicity; and in recent years many have been found to be carcinogenic.
Not so long ago, cadmium was found in children’s jewelry; and lead was discovered in the paint used on children’s toys. These and other high density metals are called “heavy metals.” In order to function properly the human body actually needs small quantities of certain heavy metals; but in excess even useful metals can be damaging. A large number of heavy metals are extremely toxic to the human body and can cause cancer and/or serious physical and mental degeneration.
Chelation therapy for cancer is a treatment that eliminates from the body harmful heavy metals and other undesirable substances that may interfere with cancer treatment and recovery. Find out more about chelation therapy for cancer on our website.
Autohemotherapy is a self-blood therapy that can be used in cancer treatment to help boost the body’s immune system response. Autohemotherapy is one of a number of beneficial cancer therapies that Issels cancer treatment teams may integrate into a patient’s comprehensive immunobiologic core treatment program.
Described in Mainstream Medicine Since 1913
First described by French physician Paul Ravaut in 1913, autohemotherapy is not an “alternative therapy,” but a mainstream medical “serum therapy” that has been used to treat a wide range of chronic disease conditions. Hundreds of articles on its use can be found in mainstream medical journals, including the Journal of the American Medical Association.
Used in Europe and South America
More commonly used in Europe and South America than in the United States, autohemotherapy involves the withdrawal of a small amount of the patient’s blood and its reinjection; usually back into the vein or into a muscle. When disease, including cancer, attacks the body, the body fights back; producing antigens and other metabolic by-products that are present in the patient’s blood.
Triggering Immune Response
By removing and then reintroducing cancer by-products back into the patient’s body, the goal of autohemotherapy is to stimulate a fresh immune system response. To enhance the immunobiologic effect of autohemotherapy, sometimes the removed blood is mixed with a homeopathic remedy or ozone before it is injected into the patient.
Many Issels patients have benefited from the inclusion of autohemotherapy in their integrative immunotherapy program (see Issels treatment reviews). However, as is true in all cancer therapies, treatment response varies with each patient. Talk to your Issels cancer treatment team about the value of including autohemotherapy in your cancer treatment program.
“We’re asking surgeons to buy a device that takes away profit margins and their next case but makes life and recovery easier for the patient. Why, in Israel and Europe, where no one is rewarded monetarily for second surgeries, do they embrace this tool?”
That’s the telling question Newport Beach, California cancer surgeon Dr. Alice Police asked the Orange County Register while discussing the reluctance of U.S. hospitals and cancer surgeons to use a game-changing new breast cancer surgery tool that dramatically reduces the need for repeat surgeries.
Using the new MarginProbe System, surgeons can test removed tissue in the operating room to determine whether all cancer cells have been excised and, if necessary, remove additional tissue during a single surgery, negating the need for subsequent surgeries. While the cost of using the device is high, FDA approval means costs are covered by Medicare and most major health insurers. So why have only 4 U.S. hospitals purchased the MarginProbe System in the 8 months since FDA approval?
Dr. Michael J. Stamos of the University of California-Irvine Medical Center said UCI purchased the device “to improve patient care.” While admitting that the hospital loses money when repeat surgeries are not needed, he told the Register, “You have to look beyond the current economics and more at favorable outcomes.”
Concern that profit margins may be affecting hospitals’ and surgeons’ reluctance to adopt this new cancer treatment tool calls into question broader treatment recommendations made by practitioners of traditional Western medicine. Do profit margins play a role in their failure to offer cancer patients effective alternative cancer treatments from which they will not profit?